Literature DB >> 8954170

In vitro analysis of cancer prevention by a mycobacterial antigen complex and of cancer-promoted inhibition of immune reactions.

H Maes1, C Cocito.   

Abstract

The antigen complex A60 of Mycobacterium bovis bacillus Calmette-Guérin protected mice against experimental tuberculous infection, and prevented cancer development after challenge with EMT 6 cells. Although humoral and cellular immune reactions elicited by A60 in vivo remained unaffected in cases of tumor rejection, they were suppressed in the case of neoplastic growth. In the present work, these in vivo observations were analyzed by in vitro techniques. Activated macrophages played a major role, and cytolytic T lymphocytes a minor role, in A60-promoted cancer cell cytolysis leading to tumor rejection. In vitro, EMT 6 cells weakly inhibited the proliferation of A60-specific B lymphocytes and strongly inhibited the functions of activated macrophages. However, the collapse of both humoral and cellular immune reactions during the course of cancer development was also accompanied by an inhibitory action of EMT 6 cells on the multiplication and functions of A60-specific T lymphocytes. Tumor-dependent repression of macrophage activation was therefore due to both a direct action of tumor cells on macrophages and an indirect one via inhibition of macrophage-activating T cell functions. On the other hand, tumor-induced collapse of the anti-A60 Ig synthesis was mainly due to inhibition of B-cell-activating T cells, with a weaker direct effect of tumor cells on B lymphocytes. Consequently, A60 and tumor cells exert opposite effects on the immune system at several levels.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8954170     DOI: 10.1007/bf01209120

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  45 in total

Review 1.  Delayed-type hypersensitivity recruitment of T cell subsets via antigen-specific non-IgE factors or IgE antibodies: relevance to asthma, autoimmunity and immune responses to tumors and parasites.

Authors:  P W Askenase
Journal:  Chem Immunol       Date:  1992

2.  Immunization of mice with the antigen A60 of Mycobacterium bovis BCG.

Authors:  R D Hubbard; C M Flory; F M Collins; C Cocito
Journal:  Clin Exp Immunol       Date:  1992-04       Impact factor: 4.330

Review 3.  Tumor antigens.

Authors:  J L Urban; H Schreiber
Journal:  Annu Rev Immunol       Date:  1992       Impact factor: 28.527

Review 4.  Antitumor activity of Corynebacterium parvum.

Authors:  L Milas; M T Scott
Journal:  Adv Cancer Res       Date:  1978       Impact factor: 6.242

Review 5.  Thermostable macromolecular antigens from mycobacteria.

Authors:  P Gilot; M Coene
Journal:  Can J Microbiol       Date:  1994-08       Impact factor: 2.419

6.  Delayed hypersensitivity reactions by the mycobacterial antigen A60 and cutaneous testing in tuberculosis.

Authors:  C Benoit; A Beschin; M Desmecht; P Dekeyser; C Cocito
Journal:  Med Microbiol Immunol       Date:  1989       Impact factor: 3.402

7.  Mycobacterial proliferation in macrophages is prevented by incubation with lymphocytes activated in vitro with a mycobacterial antigen complex.

Authors:  A Beschin; L Brijs; P De Baetselier; C Cocito
Journal:  Eur J Immunol       Date:  1991-03       Impact factor: 5.532

8.  Functional characterization of tumor-infiltrating lymphocytes, lymph-node lymphocytes and peripheral-blood lymphocytes from patients with breast cancer.

Authors:  A Rubbert; B Manger; N Lang; J R Kalden; E Platzer
Journal:  Int J Cancer       Date:  1991-08-19       Impact factor: 7.396

9.  In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2.

Authors:  P J Spiess; J C Yang; S A Rosenberg
Journal:  J Natl Cancer Inst       Date:  1987-11       Impact factor: 13.506

10.  Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.

Authors:  A Belldegrun; L M Muul; S A Rosenberg
Journal:  Cancer Res       Date:  1988-01-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.